Pfizer delivered another quarter of solid commercial execution. On August 4 the drugmaker posted second-quarter revenue of $15.03 billion. That topped Wall Street forecasts by a healthy margin. Adjusted earnings per share came in at 77 cents, beating expectations of 68 cents. Yet the headline number that moved markets was the decision to lift the low end of full-year 2026 revenue guidance.
The new range sits at $60.5 billion to $62.5 billion. Previously Pfizer had pointed to $59.5 billion to $62.5 billion. The midpoint moved up $500 million. Management cited $1.5 billion in unexpected strength from non-COVID products through the first half. That more than offset a $1 billion reduction in projected COVID-related sales. CNBC laid out the beat in clear terms the same day.
One product carried much of the weight. Eliquis, the blood thinner co-marketed with Bristol Myers Squibb, generated $2.43 billion in the quarter. Sales jumped 19 percent from a year earlier and crushed internal forecasts. Global demand stayed robust. U.S. pricing held firmer than some analysts anticipated. But here’s the catch. Eliquis faces loss of exclusivity before the end of the decade. The Motley Fool noted in its August 11 analysis that this single medicine still props up too much of the near-term story. Read the full take here.
And the official earnings release drives the point home. Launched and acquired products grew 18 percent operationally. Padcev rose 23 percent on continued uptake in bladder cancer. The Vyndaqel family expanded 8 percent as diagnosis rates improved internationally. Lorbrena posted a 37 percent gain in its niche. These wins matter. They show the portfolio diversification effort is gaining traction. Still, the aggregate lift for 2026 rests heavily on medicines already facing generic pressure down the road.
Investors appeared to agree. Shares rose modestly after the print but failed to sustain early gains. The stock traded near $26.80 in the days that followed. At that level the dividend yield hovers around 6.5 percent. Some see that payout as the main reason to own the name right now. Others worry the guidance bump simply papers over structural challenges.
CEO Albert Bourla struck an upbeat tone. “Pfizer had another strong quarter, delivering on our financial commitments and advancing our strategy,” he said in the earnings release. “Our launched and acquired products performed well, our obesity program is advancing with meaningful momentum and our oncology portfolio remains a source of strength. I am confident we will create substantial future value for patients and shareholders.” The official Pfizer Q2 2026 earnings release captured those remarks in full.
Yet the quarter also featured a $4.3 billion non-cash impairment charge. That drove a reported net loss of $248 million, or 4 cents per share. The charge related to lowered revenue expectations for certain pipeline assets, including sigvotatug vedotin and Oxbryta. Such write-downs remind investors that early bets don’t always pay off on schedule. Pipeline risk remains real even as late-stage candidates advance.
Pfizer is attacking that risk on multiple fronts. The company continues to pour resources into oncology. Recent data on Braftovi showed a 56 percent reduction in the risk of progression or death in a subset of colorectal cancer patients. Lorbrena’s seven-year follow-up in ALK-positive lung cancer reinforced its position. Regulators granted priority review to Talzenna in combination with Xtandi for metastatic castration-sensitive prostate cancer. These readouts matter for longer-term growth.
Obesity represents another priority. Berobenatide, Pfizer’s lead GLP-1 candidate, posted encouraging Phase 2 results on weight loss and tolerability. The molecule offers once-monthly dosing, a potential edge over daily or weekly competitors. Management has moved it into Phase 3. Additional oral candidates and amylin combinations sit in earlier stages. The $10 billion acquisition of Metsera, announced earlier, added further assets to this basket. Interim CFO Cecile Guegan highlighted the commitment to R&D spending even while tightening other costs.
Cost discipline forms a parallel track. Pfizer outlined an additional $2.5 billion in productivity savings targeted for 2027 through 2029. That builds on an existing program expected to deliver $6.7 billion in total net cost reductions by the end of the decade. Manufacturing optimization alone should contribute another $1.5 billion in that window. One-time charges of roughly $4 billion will hit as the company reshapes its footprint. Bourla has made clear that these moves free up capital for innovation and returns to shareholders. No share repurchases are planned for 2026. Dividends and R&D remain the focus.
The market’s muted reaction reflects a deeper tension. COVID product sales continue their expected decline. Comirnaty fell 34 percent operationally in the quarter. Paxlovid dropped 95 percent as the virus settled into an endemic pattern. Guegan noted that low incidence could keep utilization muted. Full-year COVID revenue guidance now sits at about $4 billion, down from prior assumptions. That drag must be absorbed by the core business.
Analysts have mixed views. Some credit the non-COVID acceleration and pipeline momentum. Others fixate on the patent cliff for Eliquis, Ibrance and other legacy assets. The raised guidance for 2026 helps bridge the gap. It signals confidence that current products can deliver at least low-single-digit operational growth excluding COVID and lost exclusivity impacts. Yet true acceleration is expected only after 2028 when new launches scale.
Recent insider buying adds an interesting data point. On August 12 CEO Bourla purchased 38,000 shares in the open market. Two directors bought as well. The trades, disclosed in SEC filings, totaled nearly $3 million. They occurred after the earnings release and guidance hike. While not enormous relative to the company’s size, such purchases often signal internal conviction. Reuters covered the earnings context and cost-cutting plans on the day of release.
Still, the road ahead contains uncertainties. Pricing pressure in the U.S. continues. Generic erosion will accelerate. Regulatory decisions on key oncology and immunology candidates could swing billions in future revenue. Clinical trial outcomes for the obesity portfolio carry binary risk. Investors must weigh whether the current dividend and pipeline optionality justify ownership at today’s valuation.
Pfizer’s story has evolved from pandemic hero to portfolio optimizer. The latest results show progress on both commercial execution and cost realignment. The guidance increase underscores genuine momentum outside of COVID. But the reliance on a soon-to-expire blockbuster like Eliquis underscores how much work remains. Success in obesity, next-generation oncology and other new launches will ultimately determine whether this raise marks the start of renewed growth or merely a temporary reprieve.